Sutro Biopharma, Inc. announced the appointment of Barbara Leyman, Ph.D., as Chief Business Development Officer, effective July 8, 2024. Dr. Leyman brings 20 years of life science industry business development, investing, and corporate strategy experience to Sutro. Dr. Leyman most recently served as Senior Vice President of Corporate Development at GenEdit, a developer of genetic medicines.

Prior to this role, she was a business development leader at Lyell Immunopharma and Calico Life Sciences. Before joining industry, Dr. Leyman was Head of Life Sciences Investment Fund at LRM, a venture capital firm, and worked as Licensing and New Ventures Manager at the Flanders Institute for Biotechnology (VIB). She has served on the board of directors at biopharmaceutical companies Apitope, Complix., and Amakem.

Dr. Leyman received a Ph.D. degree in Molecular Biology from Imperial College, Wye Campus, University of London and a Master?s degree in Chemistry and Biotechnology from Ghent University.